Brief: Longeveron Announces First Patient Dosed In Phase 2 Clinical Trial Of Lomecel-B™ For Aging-Related Frailty In Japan
19/04/2023 14:00
April 19 (Reuters) - Longeveron Inc LGVN.O :
* LONGEVERON ANNOUNCES FIRST PATIENT DOSED IN PHASE
2 CLINICAL
TRIAL OF LOMECEL-B™ FOR AGING-RELATED FRAILTY IN JAPAN
* LONGEVERON INC - TRIAL AIMS TO ENROLL 45 PATIENTS AND ITS
PRIMARY OBJECTIVE IS TO EVALUATE SAFETY
Source text for Eikon: ID:nGNX8ycvrF
Further company coverage: LGVN.O